GT200800297A - Formulaciones galenicas de alisquireno e hidroclorotiazida - Google Patents

Formulaciones galenicas de alisquireno e hidroclorotiazida

Info

Publication number
GT200800297A
GT200800297A GT200800297A GT200800297A GT200800297A GT 200800297 A GT200800297 A GT 200800297A GT 200800297 A GT200800297 A GT 200800297A GT 200800297 A GT200800297 A GT 200800297A GT 200800297 A GT200800297 A GT 200800297A
Authority
GT
Guatemala
Prior art keywords
hydroclorotiazida
alisquireno
galenic formulations
present
oralally
Prior art date
Application number
GT200800297A
Other languages
English (en)
Inventor
Willmann Matthias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800297(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200800297A publication Critical patent/GT200800297A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMAS DE DOSIFICACION ORAL SOLIDAS QUE COMPRENDEN UN INHIBIDOR DE RENINA ORALMENTE ACTIVO, ALISQUIRENO E HIDROCLOROTIAZIDA COMO LOS INGREDIENTES ACTIVOS EN UN MEDIO PORTADOR ADECUADO. EN PARTICULAR, LA PRESENTE INVENCION PROPORCIONA FORMULACIONES GALENICAS QUE COMPRENDEN LA SAL DE HEMI-FUMARATO DE ALISQUIRENO EN COMBINACION CON HIDROCLOROTIAZIDA DE UTILIDAD EN CUADROS DE HIPERTENSION.
GT200800297A 2006-06-23 2008-12-17 Formulaciones galenicas de alisquireno e hidroclorotiazida GT200800297A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds

Publications (1)

Publication Number Publication Date
GT200800297A true GT200800297A (es) 2009-03-09

Family

ID=36803824

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800297A GT200800297A (es) 2006-06-23 2008-12-17 Formulaciones galenicas de alisquireno e hidroclorotiazida

Country Status (26)

Country Link
US (1) US8618172B2 (es)
EP (3) EP3391878A1 (es)
JP (1) JP5362556B2 (es)
KR (1) KR101442272B1 (es)
CN (1) CN101472566A (es)
AR (1) AR061565A1 (es)
AU (1) AU2007263261B2 (es)
BR (1) BRPI0713338A2 (es)
CA (1) CA2654872A1 (es)
CL (1) CL2007001837A1 (es)
EC (1) ECSP088986A (es)
ES (1) ES2704979T3 (es)
GB (1) GB0612540D0 (es)
GT (1) GT200800297A (es)
IL (1) IL195425A (es)
MA (1) MA30527B1 (es)
MX (1) MX2008016533A (es)
MY (1) MY146779A (es)
NO (1) NO20090262L (es)
NZ (1) NZ572937A (es)
PE (2) PE20080373A1 (es)
RU (1) RU2491058C2 (es)
TN (1) TNSN08528A1 (es)
TW (1) TWI457137B (es)
WO (1) WO2007147596A1 (es)
ZA (1) ZA200809773B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009040373A2 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of aliskiren
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
US20100093603A1 (en) * 2008-07-17 2010-04-15 Kenneth Baker Use of organic compounds
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
MX363844B (es) * 2013-03-15 2019-04-05 SpecGx LLC Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
DK1507558T3 (da) * 2002-05-17 2011-12-05 Novartis Pharma Ag Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
TW200538154A (en) 2004-02-17 2005-12-01 Novartis Ag Combination of organic compounds
PE20142101A1 (es) 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
US20090247582A1 (en) * 2005-04-27 2009-10-01 Randy Lee Webb Methods of treating atherosclerosis
BRPI0617621A2 (pt) * 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos

Also Published As

Publication number Publication date
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
MY146779A (en) 2012-09-28
US8618172B2 (en) 2013-12-31
GB0612540D0 (en) 2006-08-02
KR101442272B1 (ko) 2014-09-22
CL2007001837A1 (es) 2008-06-13
EP3391878A1 (en) 2018-10-24
NO20090262L (no) 2009-01-19
ECSP088986A (es) 2009-01-30
JP2009541239A (ja) 2009-11-26
RU2009101971A (ru) 2010-07-27
WO2007147596A1 (en) 2007-12-27
TWI457137B (zh) 2014-10-21
AU2007263261A1 (en) 2007-12-27
CA2654872A1 (en) 2007-12-27
IL195425A (en) 2014-01-30
TW200808358A (en) 2008-02-16
AR061565A1 (es) 2008-09-03
PE20080373A1 (es) 2008-06-06
KR20090021353A (ko) 2009-03-03
ES2704979T3 (es) 2019-03-21
IL195425A0 (en) 2009-08-03
US20090203679A1 (en) 2009-08-13
JP5362556B2 (ja) 2013-12-11
BRPI0713338A2 (pt) 2012-03-06
ZA200809773B (en) 2009-11-25
TNSN08528A1 (en) 2010-04-14
EP2311439A1 (en) 2011-04-20
RU2491058C2 (ru) 2013-08-27
EP2034968B1 (en) 2018-10-31
NZ572937A (en) 2011-11-25
PE20120990A1 (es) 2012-08-16
AU2007263261B2 (en) 2011-07-14
CN101472566A (zh) 2009-07-01
EP2034968A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
CY1118601T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
GT200800297A (es) Formulaciones galenicas de alisquireno e hidroclorotiazida
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
PA8774901A1 (es) Productos de cuidado oral y metodos para usar y fabricar el mismo
CR11772A (es) Metodos y composicion liquidas de limpieza
GT200500181A (es) Formulaciòn herbicida
GT200600117A (es) Nuevos compuestos farmaceuticos
DE602006002260D1 (de) Insektenabweisende zusammensetzungen mit verzögerter freisetzung
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
ECSP088889A (es) Forma nueva de administración de racecadotril
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
SV2009003287A (es) Agentes para combatir parasitos en animales
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
UY29593A1 (es) Derivados de azolopiridin-2-ona como inhibidores de lipasas y fosfolipasas
CO6382113A2 (es) Compuestos quimicos
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico